Article
The drug that pleases by paralysis is no reason to party, even in the wake of FDA approval.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Shifting the Paradigm in Infant Atopic Dermatitis Treatment with Roflumilast
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
Why Plant-Derived Exosomes are Revolutionizing Regenerative Skin Care, According to Frank Roesken, MD, PhD
Hydrafacial Launches HydraFillic 9-Peptide Booster for Advanced Skin Rejuvenation